Skip to main content
Premium Trial:

Request an Annual Quote

Canopy Biosciences, OnRamp Bioinformatics Expand Informatics Partnership

NEW YORK – Canopy Biosciences said Tuesday that it is expanding an existing partnership with OnRamp Bioinformatics to offer OnRamp Bio's Rosalind cloud-based genomic informatics platform to contract research organizations that use Canopy's gene expression services.  

With Rosalind, Canopy customers will be able to visualize differential gene expression data from NanoString and RNA sequencing files, even if they lack other bioinformatics capabilities. The technology will also enable collaboration among researchers in disparate locations, according to St. Louis-based Canopy.

The company said that this work with OnRamp Bio will replace a legacy multiomics data analytics report at a time when Canopy is pushing into the clinical market in the wake of its December acquisition of biopharma services firm Core Diagnostics.

"The ability to dynamically visualize gene expression and pathway analysis while easily collaborating with your whole team is highly sought after, especially at a time when so many team members are working from home," Canopy Cofounder and COO Crystal Winkeler said in a statement. Winkeler said that Rosalind now includes COVID-19 information among the more than 50 databases it pulls information from.

A recent partnership between OnRamp Bio and NanoString Technologies will provide new informatics analysis capabilities for data generated on NanoString's nCounter system. Canopy said that it intends to make these features available to its customers through its relationship with OnRamp Bio.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.